Annette Snejbjerg Bartels
Biomedical Laboratory Scientist
Molecular and Cellular Pharmacology
Jagtvej 160, København Ø
1 - 1 out of 1Page size: 10
- 2013
- Published
Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?
Munro, A. F., Bartels, Annette Snejbjerg, Balslev, E., Twelves, C. J., Cameron, D. A., Brünner, N. & Bartlett, J. M., 2013, In: Breast Cancer Research (Online Edition). 15, 2, 8 p., R31.Research output: Contribution to journal › Journal article › Research › peer-review
ID: 6090964
Most downloads
-
864
downloads
TIMP-1 and responsiveness to gemcitabine in advanced breast cancer: results from a randomized phase III trial from the Danish breast cancer cooperative group
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
849
downloads
High frequency of tumor cells with nuclear Egr-1 protein expression in human bladder cancer is associated with disease progression
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
687
downloads
Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer
Research output: Contribution to journal › Journal article › Research › peer-review
Published